Amendm nts to the claims

1. (currently amended) A compound of Formula (I):



(I)

or a stereoisomer, or pharmaceutically acceptable salt form thereof, wherein:

A^1 is C_1-C_3 alkylene substituted by 0-2 C_1-C_4 alkyl;

A^2 is $-A^3-R^{9a}$;

W is $-B(OR^{26})(OR^{27})$;

R^1 is selected from the group: H, F;

C_1-C_6 alkyl substituted with 0-3 R^{1a};

C_2-C_6 alkenyl substituted with 0-3 R^{1a};

C_2-C_6 alkynyl substituted with 0-3 R^{1a}; and

C_3-C_6 cycloalkyl substituted with 0-3 R^{1a};

R^{1a} is selected at each occurrence from the group:

Cl, F, Br, I, CF_3, CHF_2, OH, =O, SH;

R^2 is selected from the group: H, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_3-C_4 cycloalkyl, and C_3-C_4 cycloalkyl(C_1-C_4 alkyl)-;

R^3 is selected from the group: R^4,

$-(CH_2)_p-NH-R^4$,

$-(CH_2)_p-NHC(=O)-R^4$,

$-(CH_2)_p-C(=O)NH-R^4$,

$-(CH_2)_p-C(=O)O-R^4$,

$-(CH_2)_p-C(=O)C(=O)-R^4$,

$-(CH_2)_p-C(=O)C(=O)NH-R^4$,

$-(CH_2)_p-NHC(=O)NH-R^4$,

$-(CH_2)_p-NHC(=O)NHC(=O)-R^4$,

$-(CH_2)_p-NHS(=O)_2-R^4$,

$-(CH_2)_p-S(=O)_2NH-R^4$,

$-(CH_2)_p-C(=O)-R^4$,

$-(CH_2)_p-O-R^4$, and

$-(CH_2)_p-S-R^4$;

p is 0, 1, or 2;

R^4 is selected from the group:

C_1-C_6 alkyl substituted with 0-3 R^{4a};

C_2-C_6 alkenyl substituted with 0-3 R^{4a};

C_2-C_6 alkynyl substituted with 0-3 R^{4a}; and

~~C_3-C_{10} cycloalkyl substituted with 0-4 R^{4b};~~

C_3-C_{10} carbocycle substituted with 0-4 R^{4b};

~~aryl substituted with 0-5 R^{4b}; and~~

~~aryl-C_1-C_4 alkyl substituted with 0-5 R^{4b};~~

R^{4a} is, at each occurrence, independently selected from:

H,

C_1-C_4 alkyl substituted with 0-3 R^{4b};

C_2-C_4 alkenyl substituted with 0-3 R^{4b};

C_2-C_4 alkynyl substituted with 0-3 R^{4b}; and

~~C_3-C_7-cycloalkyl-substituted with 0-4 R^{4c};~~

C_3-C_{10} carbocycle substituted with 0-4 R^{4c}; ~~and~~

~~aryl substituted with 0-5 R^{4c};~~

R^{4b} is, at each occurrence, independently selected from:

H,

C_1-C_4 alkyl substituted with 0-3 R^{4c};

C_2-C_4 alkenyl substituted with 0-3 R^{4c};

C_2-C_4 alkynyl substituted with 0-3 R^{4c};

C_3-C_6 cycloalkyl substituted with 0-4 R^{4d}; and

aryl substituted with 0-5 R^{4d};

R^{4c} is, at each occurrence, independently selected from:

H,

C_1-C_4 alkyl substituted with 0-3 R^{4d};

C_2-C_4 alkenyl substituted with 0-3 R^{4d};

C_2-C_4 alkynyl substituted with 0-3 R^{4d};

C_3-C_6 cycloalkyl substituted with 0-4 R^{4d}; and

aryl substituted with 0-5 R^{4d};

R^{4d} is, at each occurrence, independently selected from:

H, F, Cl, Br, I, $-NO_2$, -CN, -NCS, $-CF_3$, $-OCF_3$, =O, OH,

R^{9a} is selected from the group: H, ~~$-S(=O)_2R^{9b}$,~~
$-C(=O)R^{9b}$, $-C(=O)OR^{9b}$, $-C(=O)NHR^{9b}$, $-C(=O)NHC(=O)R^{9b}$;
C_1-C_6 alkyl substituted with 0-3 R^{9c};
C_2-C_6 alkenyl substituted with 0-3 R^{9c}; and
C_2-C_6 alkynyl substituted with 0-3 R^{9c};

R^{9b} is selected from the group: H;
C_1-C_6 alkyl substituted with 0-3 R^{9c};
C_2-C_6 alkenyl substituted with 0-3 R^{9c};
C_2-C_6 alkynyl substituted with 0-3 R^{9c}; and
~~C_3-C_6-cycloalkyl substituted with 0-3 R^{9d};~~
C_3-C_{14} carbocycle substituted with 0-4 R^{9d}; ~~and~~
~~aryl substituted with 0-5 R^{9d};~~

R^{9c} is selected from the group:
C_1-C_6 alkyl substituted with 0-3 R^{9d};
C_2-C_6 alkenyl substituted with 0-3 R^{9d};
C_2-C_6 alkynyl substituted with 0-3 R^{9d}; and
~~C_3-C_6-cycloalkyl substituted with 0-3 R^{9e};~~
C_3-C_{14} carbocycle substituted with 0-4 R^{9e}; ~~and~~
~~aryl substituted with 0-5 R^{9e};~~

R^{9d} is selected at each occurrence from the group:
C_1-C_4 alkyl substituted with 0-3 R^{9e};
C_1-C_4 alkoxy substituted with 0-3 R^{9e};
C_3-C_6 cycloalkyl substituted with 0-3 R^{9e}; and

aryl substituted with 0-5 R^{9e};

R^{9e} is selected at each occurrence from the group:
C_1-C_4 alkyl, C_1-C_4 alkoxy, CF_3, OCF_3, Cl, F, Br, I, =O, OH, phenyl, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, -CN, and NO_2;

R^{11} ~~and R^{11a} are, at each occurrence, independently~~ is selected from the group: H;
C_1-C_6 alkyl substituted with 0-3 R^{11b};
C_2-C_6 alkenyl substituted with 0-3 R^{11b};
C_2-C_6 alkynyl substituted with 0-3 R^{11b};
C_3-C_7 cycloalkyl substituted with 0-3 R^{11b};
aryl substituted with 0-3 R^{11b}; and
aryl(C_1-C_4 alkyl)- substituted with 0-3 R^{11b};

R^{11b} is OH, C_1-C_4 alkoxy, F, Cl, Br, I, NH_2, or -NH(C_1-C_4 alkyl);

OR^{26} and OR^{27} ~~are independently selected from:~~
~~a) OH,~~
~~b) C_1-C_8 alkoxy, and~~
, when taken together, ~~OR^{26} and OR^{27}~~ form a cyclic boronic ester where said cyclic boronic ester contains from 2 to 20 carbon atoms; and

A^3 is valine.

2. (currently amended) A compound of Claim 1, or a stereoisomer, or a pharmaceutically acceptable salt form thereof, wherein:

A^1 is $-CH_2-$;

R^1 is selected from the group: H,
C_1-C_6 alkyl;
C_2-C_6 alkenyl; and
C_2-C_6 alkynyl;

R^2 is H;

R^3 is selected from the group:
C_1-C_6 alkyl substituted with phenyl,
C_1-C_6 alkenyl substituted with phenyl, and
$-CH_2CONHPh$~~, and~~
~~(2-phenylquinolin-4-yl)methyl~~;

and OR^{26} and OR27 ~~when~~ taken together form pinanediol.

3. (previously canceled)

4. (previously canceled)

5. (previously canceled)

6. (previously canceled)

7. (currently amended) A compound of Claim 1, or a stereoisomer or a pharmaceutically acceptable salt form thereof, selected from the group consisting of

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-3-methyl-2-[(phenylacetyl)-amino]-butanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

tert-butyl (1*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}amino)carbonyl]-2-oxo-3-(3-phenylpropyl)imidazolidinyl]carbonyl}-2-methylpropylcarbamate;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-2-[(anilinocarbonyl)amino]-3-methylbutanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-2-[(9*H*-fluoren-1-ylcarbonyl)amino]-3-methylbutanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-((2*S*)-2-{[(4-methoxyphenyl)acetyl]amino}-3-methylbutanoyl)-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-butenyl}-3-{(2*S*)-2-[(9*H*-fluoren-1-ylcarbonyl)amino]-3-methylbutanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

9*H*-fluoren-9-ylmethyl (1*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}amino)carbonyl]-2-oxo-3-(3-phenylpropyl)imidazolidinyl]carbonyl}-2-methylpropylcarbamate;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-((2*S*)-3-methyl-2-{[3-(trifluoromethyl)benzyl]amino}butanoyl)-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-2-[([1,1'-biphenyl]-4-ylmethyl)amino]-3-methylbutanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

~~9*H*-fluoren-9-ylmethyl (1*S*)-1-({(5*S*)-5-[({(1*R*)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}amino)carbonyl]-2-oxo-3-[(2-phenyl-4-quinolinyl)methyl]imidazolidinyl}carbonyl)-2-methylpropylcarbamate;~~

~~*N*-((1*S*)-1-{[(5*S*)-5-({[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-amino)carbonyl]-2-oxo-3-(3-phenylpropyl)imidazolidinyl]carbonyl}-2-methylpropyl)-2-chloronicotinamide;~~

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-2-[(4-

butylbenzoyl)amino]-3-methylbutanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

isobutyl (1*S*)-1-{[(5*S*)-5-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}amino)carbonyl]-2-oxo-3-(3-phenylpropyl)imidazolidinyl]carbonyl}-2-methylpropylcarbamate;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-((2*S*)-2-{[(benzoylamino)carbonyl]amino}-3-methylbutanoyl)-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-[(2*S*)-3-methyl-2-(1-naphthoylamino)butanoyl]-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-[(2*S*)-2-(acetylamino)-3-methylbutanoyl]-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-[(2*S*)-2-(benzoylamino)-3-methylbutanoyl]-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

benzyl (5*S*)-5-[({(1*R*)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-

butenyl}amino)carbonyl]-2-oxo-3-[(2*E*)-3-phenyl-2-propenyl]-1-imidazolidinecarboxylate; and

benzyl (5*S*)-5-[({(1*R*)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-butenyl}amino)carbonyl]-3-(2-anilino-2-oxoethyl)-2-oxo-1-imidazolidinecarboxylate.

8. (previously amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt form thereof.

9. (previously canceled)

10. (previously canceled)

11. (previously canceled)

12. (previously canceled)

13. (previously canceled)

14. (previously canceled)

15. (previously canceled)

16. (previously canceled)

17. (previously canceled)

18. (previously canceled)

19. (previously canceled)

20. (previously canceled)

21. (previously canceled)

22. (previously canceled)